DSW Ventures leads £500k investment into Newcastle-based biotech InvenireX

InvenireX, a Newcastle-based biotech company that aims to disrupt the market for PCR laboratory tests, has raised £500,000 in funding from DSW Ventures and XTX Ventures.

From L to R: Bradley Brown, Josie Todd, Daniel Todd and David Markham

InvenireX’s platform, which incorporates AI and programmable DNA, or ‘nanites’, enables scientists to rapidly test raw materials for biomarkers at minute concentrations without the need for pre-processing. It could have wide-ranging applications in early disease detection, personalised medicine, and environmental monitoring.

Currently, PCR (polymerase chain reaction) tests are widely used to detect the presence of genetic material but are time-consuming and prone to error. Samples have to be purified and amplified, which can generate false readings, and repeat tests can produce varied results. InvenireX has developed a fundamentally new process that is simpler and more accurate: the raw sample is input directly into the instrument and provides real-time, highly sensitive, and user-friendly outputs.

InvenireX was founded in 2021 by Daniel Todd while studying for a PhD in DNA and nanotechnology at the University of Newcastle. The company, which is based in Newcastle city centre and has a four-strong team, is currently engaged in two proof-of-concept studies with commercial partners in the fields of agriculture and cancer detection. The funding will enable it to optimise the final prototype and deploy it in external R&D laboratories for further technical validation.

Daniel Todd, founder, said: “This funding is a significant milestone for InvenireX and is a testament to our groundbreaking work in the realm of enzyme-free real-time, ultrasensitive nucleic-acid detection and absolute quantification. The expertise and financial support from DSW and XTX will be instrumental in accelerating our route to market.  We look forward to working closely with them as we embark on this exciting phase of growth and innovation.”

InvenireX becomes the 13th company to join the DSW Ventures portfolio and the second from its recently launched Seed EIS fund.

Emma Cassidy of DSW Ventures commented: “InvenireX has developed an exciting platform technology with promising data and early customer traction. This round will help get the technology into the hands of users who can further validate it and drive the company forward into full commercialisation. It’s been a pleasure to work with the InvenireX team who are incredibly talented, dynamic and open to collaboration.”

Weightmans LLP (legal) advised DSW Ventures on the deal, with Ward Hadaway advising InvenireX.